<DOC>
	<DOCNO>NCT01412229</DOCNO>
	<brief_summary>This non-randomized , open-label phase II trial 40 patient poor prognosis head neck cancer , define surgically unresectable and/or ≥N2b disease judge appropriate non-surgical definitive therapy .</brief_summary>
	<brief_title>Induction Chemotherapy Locally Advanced Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>This non-randomized , open-label phase II trial 40 patient poor prognosis head neck cancer , define surgically unresectable and/or ≥N2b disease judge appropriate non-surgical definitive therapy . Patients must ECOG performance status 0-1 good organ function treat six weekly cycle carboplatin , nab-paclitaxel cetuximab prior schedule concomitant chemoradiation . The study design evaluate whether induction regimen result improve response rate ( complete response ( CR ) + partial response ( PR ) ) less toxicity current standard induction TPF regimen include docetaxel , cisplatin 5-fluorouracil ( 5FU ) .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically cytologically confirm SCCHN poorly differentiate undifferentiated cancer head neck . Measurable disease . All primary site eligible exclude nasopharyngeal . Surgically unresectable and/or N2b great nodal disease ; NOTE : surgical unresectability define combination treat surgeon 's judgment unresectability plus one follow objective criterion : Encasement tumor node carotid artery ¾ encasement carotid artery . Involvement prevertebral musculature Invasion bone skull base Need glossectomy extensive glossal resection functional outcome consider unacceptable surgeon patient Involvement cervical spine Severe , unacceptable functional deficit would result propose definitive surgical resection . ECOG performance status 01 Prior therapy : Chemotherapy : No prior chemotherapy treatment SCCHN . Platinum chemotherapy : No previous history carboplatin cisplatin therapy . Nabpaclitaxel : No previous treatment nabpaclitaxel another taxane . Cetuximab : No previous treatment cetuximab Or another EGFR inhibitor . Radiation therapy : No prior radiation head neck region . Age &gt; = 18 year . Men woman eligible participation . Must acceptable organ marrow function define . Laboratory test complete within 14 day prior registration : ANC &gt; = 1,500/mm3 Platelets &gt; = 100,000/mm3 HgB &gt; 9g/dL Total bilirubin &lt; = 1.5mg/dL Albumin &gt; 2.5 g/dL AST ( SGOT ) /ALT ( SGPT ) &lt; = 2.5X institutional upper limit normal , alkaline phosphatase &lt; 2.5 x upper limit normal , GFR &gt; 30 mL/min ( standard Cockcroft Gault formula measure via 24 hour urine collection ) No preexist neuropathy great grade I Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior day 1 study treatment . Women childbearing potential men must agree use adequate contraception prior study entry , duration study participation three month complete treatment . Adequate contraception define medically recommend method ( combination method ) per standard care . Patients must ability understand willingness sign write informed consent document . Patients must negative result preform IgE antibody galactosealpha1,3 , galactose . Prior treatment study medication . Prior radiation field require treat tumor . Any metastatic disease . The patient may prior malignancy must diseasefree three year prior study entry . A history superficial nonmelanoma skin cancer situ carcinoma cervix less three year allow . Pregnant lactate female Uncontrolled intercurrent illness include , limited , ongoing active infection require IV antibiotic , psychiatric illness/social situation would limit compliance study requirement . Cardiac disease symptomatic congestive heart failure , unstable angina pectoris , myocardial infarction result exclusion active within past six month . Cardiac dysrhythmia result exclusion active symptomatic ( example , ratecontrolled atrial fibrillation result exclusion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Head neck cancer</keyword>
	<keyword>Phase II</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Squamous Cell</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Induction</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>